Atgen Co. Ltd.

Atgen Co. Ltd.
Stock Exchange Korea Exchange
EPS
KRW787.5
Market Cap
KRW381.7 B
Shares Outstanding
24.71 M
Public Float
20.47 M

Profile

Address
1st & 6th Floor, Health Care Park
Seongnam-si GY 13605
Korea, Republic Of
Employees -
Website http://www.nkvue.com
Updated 09/14/2018
ATGen Co., Ltd. engages in the development, manufacture, and sale of recombinant proteins and monoclonal antibodies. Its products include NK cells under NK Vue brand, recombinant proteins, and monoclonal antibodies. The company was founded on January 14, 2002 and is headquartered at Seongnam-si, South Korea.

Financials

View All
Created with Highcharts 5.0.14Atgen Co. Ltd.Net Income. Fiscal year is January-December. All values KRW Millions.3 1813 1815 8405 8405 3745 3744 8374 83716 63216 6322013201420152016201705k10k15k20k
Created with Highcharts 5.0.14Atgen Co. Ltd.Sales/Revenue. Fiscal year is January-December. All values KRW Millions.1 5031 5031 6781 6782 5132 5136 8766 8764 8304 8302013201420152016201702k4k6k8k

Sang-Woo Park
Chief Executive Officer & Director
Yong-Hwan Cho
Senior Managing Director & Head-Operations